In Children and Adolescents (Ages 6-17) With Attention Deficit Hyperactivity Disorder (ADHD), How Does Viloxazine Extended-Release (ER) Compare with Placebo or Other ADHD Medications in Terms of Improving ADHD Symptoms, Adverse Events and Treatment Discontinuation Rates? A Systematic Review
Aims: In this systematic review, the effectiveness and safety of viloxazine ER in the treatment of ADHD in children and adolescents aged between 6–17 years will be assessed.
Saved in:
| Main Authors: | , , , , |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
Cambridge University Press
2025-06-01
|
| Series: | BJPsych Open |
| Online Access: | https://www.cambridge.org/core/product/identifier/S2056472425101981/type/journal_article |
| Tags: |
Add Tag
No Tags, Be the first to tag this record!
|
| _version_ | 1849316483626172416 |
|---|---|
| author | Khushboo Kansal Betsy Marina Babu Gaurav Uppal Nadia Liaqat Asha Dhandapani |
| author_facet | Khushboo Kansal Betsy Marina Babu Gaurav Uppal Nadia Liaqat Asha Dhandapani |
| author_sort | Khushboo Kansal |
| collection | DOAJ |
| description | Aims: In this systematic review, the effectiveness and safety of viloxazine ER in the treatment of ADHD in children and adolescents aged between 6–17 years will be assessed. |
| format | Article |
| id | doaj-art-92b217015b5d4d3684c414efb7dd054e |
| institution | Kabale University |
| issn | 2056-4724 |
| language | English |
| publishDate | 2025-06-01 |
| publisher | Cambridge University Press |
| record_format | Article |
| series | BJPsych Open |
| spelling | doaj-art-92b217015b5d4d3684c414efb7dd054e2025-08-20T03:51:43ZengCambridge University PressBJPsych Open2056-47242025-06-0111S22S2210.1192/bjo.2025.10198In Children and Adolescents (Ages 6-17) With Attention Deficit Hyperactivity Disorder (ADHD), How Does Viloxazine Extended-Release (ER) Compare with Placebo or Other ADHD Medications in Terms of Improving ADHD Symptoms, Adverse Events and Treatment Discontinuation Rates? A Systematic ReviewKhushboo Kansal0Betsy Marina Babu1Gaurav Uppal2Nadia Liaqat3Asha Dhandapani41Nottinghamshire NHS Trust, Nottingham, United Kingdom2London and KSS school of Psychiatry, London, United Kingdom3Satyam Hospital, Ludhiana, India4East London NHS, London, United Kingdom5BCUHB, Wrexham, United KingdomAims: In this systematic review, the effectiveness and safety of viloxazine ER in the treatment of ADHD in children and adolescents aged between 6–17 years will be assessed.https://www.cambridge.org/core/product/identifier/S2056472425101981/type/journal_article |
| spellingShingle | Khushboo Kansal Betsy Marina Babu Gaurav Uppal Nadia Liaqat Asha Dhandapani In Children and Adolescents (Ages 6-17) With Attention Deficit Hyperactivity Disorder (ADHD), How Does Viloxazine Extended-Release (ER) Compare with Placebo or Other ADHD Medications in Terms of Improving ADHD Symptoms, Adverse Events and Treatment Discontinuation Rates? A Systematic Review BJPsych Open |
| title | In Children and Adolescents (Ages 6-17) With Attention Deficit Hyperactivity Disorder (ADHD), How Does Viloxazine Extended-Release (ER) Compare with Placebo or Other ADHD Medications in Terms of Improving ADHD Symptoms, Adverse Events and Treatment Discontinuation Rates? A Systematic Review |
| title_full | In Children and Adolescents (Ages 6-17) With Attention Deficit Hyperactivity Disorder (ADHD), How Does Viloxazine Extended-Release (ER) Compare with Placebo or Other ADHD Medications in Terms of Improving ADHD Symptoms, Adverse Events and Treatment Discontinuation Rates? A Systematic Review |
| title_fullStr | In Children and Adolescents (Ages 6-17) With Attention Deficit Hyperactivity Disorder (ADHD), How Does Viloxazine Extended-Release (ER) Compare with Placebo or Other ADHD Medications in Terms of Improving ADHD Symptoms, Adverse Events and Treatment Discontinuation Rates? A Systematic Review |
| title_full_unstemmed | In Children and Adolescents (Ages 6-17) With Attention Deficit Hyperactivity Disorder (ADHD), How Does Viloxazine Extended-Release (ER) Compare with Placebo or Other ADHD Medications in Terms of Improving ADHD Symptoms, Adverse Events and Treatment Discontinuation Rates? A Systematic Review |
| title_short | In Children and Adolescents (Ages 6-17) With Attention Deficit Hyperactivity Disorder (ADHD), How Does Viloxazine Extended-Release (ER) Compare with Placebo or Other ADHD Medications in Terms of Improving ADHD Symptoms, Adverse Events and Treatment Discontinuation Rates? A Systematic Review |
| title_sort | in children and adolescents ages 6 17 with attention deficit hyperactivity disorder adhd how does viloxazine extended release er compare with placebo or other adhd medications in terms of improving adhd symptoms adverse events and treatment discontinuation rates a systematic review |
| url | https://www.cambridge.org/core/product/identifier/S2056472425101981/type/journal_article |
| work_keys_str_mv | AT khushbookansal inchildrenandadolescentsages617withattentiondeficithyperactivitydisorderadhdhowdoesviloxazineextendedreleaseercomparewithplaceboorotheradhdmedicationsintermsofimprovingadhdsymptomsadverseeventsandtreatmentdiscontinuationratesasystematicreview AT betsymarinababu inchildrenandadolescentsages617withattentiondeficithyperactivitydisorderadhdhowdoesviloxazineextendedreleaseercomparewithplaceboorotheradhdmedicationsintermsofimprovingadhdsymptomsadverseeventsandtreatmentdiscontinuationratesasystematicreview AT gauravuppal inchildrenandadolescentsages617withattentiondeficithyperactivitydisorderadhdhowdoesviloxazineextendedreleaseercomparewithplaceboorotheradhdmedicationsintermsofimprovingadhdsymptomsadverseeventsandtreatmentdiscontinuationratesasystematicreview AT nadialiaqat inchildrenandadolescentsages617withattentiondeficithyperactivitydisorderadhdhowdoesviloxazineextendedreleaseercomparewithplaceboorotheradhdmedicationsintermsofimprovingadhdsymptomsadverseeventsandtreatmentdiscontinuationratesasystematicreview AT ashadhandapani inchildrenandadolescentsages617withattentiondeficithyperactivitydisorderadhdhowdoesviloxazineextendedreleaseercomparewithplaceboorotheradhdmedicationsintermsofimprovingadhdsymptomsadverseeventsandtreatmentdiscontinuationratesasystematicreview |